Ceapro

Ceapro — Investor Presentation (April 2018)

28 slides from Ceapro's investor presentation, April 2018

  1. Slide 1: Enhancing Life Through Nature

    Enhancing Life Through Nature Corporate Presentation TSX: CZO April 2018 www.ceapro.com

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of product development and launches. Although the Company believ

  3. Slide 3: Corporate Overview

    Corporate Overview Focused on the development and commercialization of active ingredients for healthcare and cosmetic industries leveraging proprietary delivery systems Industry leading extraction manufacturing processes produce high value active ingredients from natural plant based sources Two valu

  4. Slide 4: Key Management and Board

    Key Management and Board Key Management Board of Directors Glenn R. Rourke, MBA - Chair of the Board Gilles Gagnon, M.Sc., MBA - Retired Senior Vice President/Managing Director, BMO Financial Group President and Chief Executive Officer - Over 30 years of experience in the pharmaceutical industry whe

  5. Slide 5: Diversified Business Model Expected to Drive Growth

    Diversified Business Model Expected to Drive Growth Revenue Generating Base Business Multiple Growth Opportunities Enabling Cosmeceuticals Nutraceuticals Technologies 5

  6. Slide 6: Unique Bioprocessing Expertise

    Unique Bioprocessing Expertise Identification, extraction and purification of active compounds from natural sources Create innovative ingredients for the personal care and healthcare industries Two value-driving bioactives at core of base business in cosmeceuticals - Beta glucan - Avenanthramides 6

  7. Slide 7: Beta Glucan

    Beta Glucan Water soluble fibre found in the cell walls of oat kernels Highly effective in stimulating collagen synthesis Key Benefits: - Skin restructuring and wound healing - Replenishes and protects the skin’s moisture barrier - Proven to effectively reduce fine lines and wrinkles, decreasing the

  8. Slide 8: Avenanthramides

    Avenanthramides Group of polyphenol compounds found exclusively in oats Antihistamine and anti-inflammatory properties - Provides relief for a host of skin conditions, such as eczema, chicken pox and insect bites Potential benefits in the control of inflammation-based diseases Ceapro is the only com

  9. Slide 9: Avenanthramides Clinically Proven in Cosmeceuticals

    Avenanthramides Clinically Proven in Cosmeceuticals Significant improvements in erythema symptoms associated in subjects with mild to moderate atopic dermatitis - 40% improvement in itch perception after 1 week - 62% of patients showed an improvement in their skin condition Subjects with atopy - 89%

  10. Slide 10: Base Business: Cosmeceuticals From Field to Formulation

    Base Business: Cosmeceuticals From Field to Formulation Revenue generating base business in personal care cosmetic market Consistent growth of at least 20% year-over-year growth Strategy focused on strengthening and expanding business by continuing to explore and clinically validate new product appl

  11. Slide 11: Beta Glucan and Avenanthramides in Multiple Household Name Products

    Beta Glucan and Avenanthramides in Multiple Household Name Products Aveeno Coppertone Jergens Dove Lubriderm Burt’s Bees 3M – Nexcare The Body Shop KY Products Philosophy Neutrogena ROC 11

  12. Slide 12: JuventeDC - Proprietary Line of Cosmeceutical Products

    JuventeDC - Proprietary Line of Cosmeceutical Products Acquisition of JuventeDC in October 2017 marks important step in strategic market diversification business plan Represents opportunity in a $5B market Utilizes two value-driving active ingredients beta glucan and avenanthramides Anti-aging skin

  13. Slide 13: Multiple High Value Growth Opportunities

    Multiple High Value Growth Opportunities ✓ Cosmeceuticals Nutraceuticals Enabling Technologies 13

  14. Slide 14: Fueling Our Nutraceuticals Pipeline From Plant to Pill

    Fueling Our Nutraceuticals Pipeline From Plant to Pill Functional Drink Cholesterol Exercised Induced Inflammation 14

  15. Slide 15: Beta Glucan: Functional Drink - Energy Booster

    Beta Glucan: Functional Drink - Energy Booster Collaborating with the University of Alberta to develop a functional drink Impregnated beta glucan, as a delivery system, with the well- known co-enzyme Q10 as an energy booster Demonstrated first water soluble formulation of co-enzyme Q10 utilizing PGX

  16. Slide 16: Comparison of CoQ10 Dispersion Stability

    Comparison of CoQ10 Dispersion Stability Commercial: CoQ10 + Cyclodextrin Ceapro’s iBG: CoQ10 + PGX β-Glucan Sample Preparation: - Both contain 100 mg of CoQ10 - Both dissolved at 40°C in 250 mL of water Picture taken 18 hours after stirring

  17. Slide 17: Beta Glucan Clinical Study: Cholesterol Reducer

    Beta Glucan Clinical Study: Cholesterol Reducer Oat Beta Glucan Linked to Cholesterol Reduction and/or Reduced Risk of Heart Disease Collaborating with prestigious Montreal Heart Institute (MHI) to assess beta-glucan as a cholesterol-lowering agent Planning to initiate multicenter, randomized, doubl

  18. Slide 18: Avenanthramides: Exercise-Induced Inflammation

    Avenanthramides: Exercise-Induced Inflammation Collaborating with the University of Minnesota to develop a functional food to alleviate exercise-induced inflammation Results from bioavailability study demonstrated a significant reduction of inflammation biomarkers in the blood Results from bio-effic

  19. Slide 19: Immuno-Regulatory and Anti-Inflammatory Effects of AVA in Eccentric Exercise-Induced Muscle Damage

    Immuno-Regulatory and Anti-Inflammatory Effects of AVA in Eccentric Exercise-Induced Muscle Damage Oxidative stress Oat Avenanthramides (AVA) Inflammation Delay Onset Muscle Soreness Eccentric Contraction (DOMS) Vertical jump Vertical jump (1) Chemokines and Adhesion Molecules Soreness rating Sorene

  20. Slide 20: Immuno-Regulatory and Anti-Inflammatory Effects of AVA: Biomarkers

    Immuno-Regulatory and Anti-Inflammatory Effects of AVA in Eccentric Exercise-Induced Muscle Damage Biomarkers • CK and CD Markers • Chemoattractants (MCP-1, E-Selectin, G-CSF, GM-CSF, ICAM-1, VCAM-1) • Inflammatory Markers: IL-1, IL-6, TNF-alpha, IL-8 • Anti-inflammatory Markers: IL-10, IL-1ra 20

  21. Slide 21: Potential For Multiple Value-Driving Opportunities

    Potential For Multiple Value-Driving Opportunities Pressurized Gas Expanded (PGX) Liquid – Spray Drying • Novel spray drying technique for processing water-soluble biopolymers • Platform that can produce numerous morphologies of biopolymers ranging from fine fibers to granular powder, which are high

  22. Slide 22: Enabling Technologies Have Broad Utility

    Enabling Technologies Have Broad Utility 22

  23. Slide 23: Pressurized Gas eXpansion Technology (PGX)

    Pressurized Gas eXpansion Technology (PGX) PGX is poised to be a delivery system platform Successfully completed impregnation of bioactives using PGX Technology for improved characteristics Pilot Scale Facility completed and custom designed equipment installed - Proprietary equipment will enable pro

  24. Slide 24: New Bio-Processing Facility

    New Bio-Processing Facility R&D Pilot Scale Capability Commercial Production New 30,000 sq. ft. GMP Bio- processing Extraction Facility in Edmonton, Alberta, Canada 24

  25. Slide 25: Financial Profile

    Financial Profile TSX-V: CZO Stock Ticker $36.6M Market capitalization as of March 19, 2018 74.8M Common shares outstanding $12,926,000 Total sales for the full year 2016 25

  26. Slide 26: Future Growth Marked by Potential to Address Significant Market Opportunities

    Future Growth Marked by Potential to Address Significant Market Opportunities Cosmetic Injectables $686M Functional Cosmetic Food Skincare $240B $5B Anti- Diabetes inflammatory Tx $57.8B $21.4B Functional Drink $17B 26

  27. Slide 27: Investment Highlights

    Investment Highlights ✓ Revenue generating, de-risked business model supports near-term and future growth ✓ Strategy focused on strengthening base cosmeceuticals business and expanding into multiple growth markets ✓ Two value-driving active ingredients used in multiple household name cosmetics and p

  28. Slide 28: Enhancing Life Through Nature

    Enhancing Life Through Nature Corporate Presentation TSX: CZO www.ceapro.com

Ceapro — Investor Presentation (April 2018) on 6ix